ClinicalTrials.Veeva

Menu
I

Irmandade da Santa Casa de Misericordia de Porto Alegre | Research Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Bevacizumab
PF-02341066
Baricitinib
Rocatinlimab
Leucovorin
Bardoxolone Methyl
Pegcetacoplan
Sunitinib
LY3009104

Parent organization

This site is a part of Irmandade da Santa Casa de Misericordia de Porto Alegre

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 48 total trials

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
Drug: Pembrolizumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Active, not recruiting
Gastroesophageal Adenocarcinoma
Gastric Neoplasms
Drug: Tislelizumab
Drug: Capecitabine

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Active, not recruiting
Advanced Solid Tumor
Drug: INCB099280

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab comp...

Active, not recruiting
Childhood Idiopathic Nephrotic Syndrome
Drug: Diphenhydramine Hydrochloride
Drug: MMF

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo
Locations recently updated

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tum...

Enrolling
Cancer
Drug: Temozolomide
Drug: Capecitabine

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients wh...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Drug: Pegcetacoplan

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Enrolling
Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Drug: Tarlatamab
Drug: Durvalumab

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal ca...

Enrolling
Metastatic Colorectal Cancer
Drug: FOLFIRI Regimen
Drug: Bevacizumab-awwb

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Domvanalimab
Drug: Nab-paclitaxel

Trial sponsors

Amgen logo
Pfizer logo
A
Incyte logo
Lilly logo
Novo Nordisk logo
Reata Pharmaceuticals logo
Roche logo
AbbVie logo
Acceleron Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems